Patient with large ecchymosis resulting from disseminated intravascular coagulation.
* Blood volume
The most important factor in the management of hypovolaemic shock is to restore the circulating blood volume as rapidly as possible. Profound or prolonged hypotension will exacerbate damage to tissues or organs and predispose to disseminated intravascular coagulation. Mortality after massive transfusion increases with the duration and severity of the shock.
Blood volume may initially be restored with crystalloid and synthetic colloid solutions. As soon as blood loss and fluid replacement reach 40% of blood volume, replacement of red cells is required. Although red cells or red cells suspended in additive solutions can initially be used, it is preferable to use whole blood after the first four units of a massive transfusion (eight or more units) because the plasma will provide both the coagulation factors and the protein needed to maintain haemostasis and colloid osmotic pressure, respectively.
As soon as the need for massive transfusion is recognised, blood samples should be taken for certain minimal laboratory tests, the results of which will be available within 15 minutes.
* Blood transfusion
The blood transfusion laboratory should be informed of the expected need for massive transfusion and the urgency for transfusion. 
Conclusion
The examples of warning labels are reproduced by kind permission of Dr H Dodsworth.
Dr Patricia E Hewitt is deputy director, North London Blood Transfusion Centre, and Dr Samuel J Machin is consultant haematologist, Middlesex Hospital, London.
* Oxygen canying capacity Modern anticoagulant preservative solutions (for example, citrate phosphate dextrose adenine) for red cells ensure adequate concentrations of 2, 3-diphosphoglycerate and therefore of oxygen carrying capacity for up to 14 days after collection of the blood. Reduced oxygen carrying capacity is likely to be important only in patients with pre-existing cardiac disease or severe anaemia. It is sensible, however, to use blood that is less than 14 days old.
* Metabolic disturbances
Hypocalcaemia is theoretically a problem, but clinical consequences are rare and complications as a result of calcium given "prophylactically" are possibly more harmful than hypocalcaemia.
Hyperkalaemia is usually transient and unimportant. The combination of hypocalcaemia and hyperkalaemia, exacerbated by hypothermia caused by rapid transfusion of blood stored at 4°C, however, can cause cardiac irregularities and electrocardiographic monitoring is advisable.
Citrate toxicity is unlikely to be a problem. Unless there is liver dysfunction, citrate is metabolised rapidly; transfusion rates of one unit of blood every five minutes must be exceeded before the citrate metabolism is overwhelmed.
Although stored blood has a reduced pH, acidosis in recipients of massive transfusions is rare because metabolism of citrate produces an alkalosis. Routine use of alkalising agents should therefore be avoided. Prolonged hypoperfusion and shock are more likely to cause acidosis; the need for alkalising agents should be judged by the results of laboratory tests and not by the number of units of blood transfused. * Plasma colloid osmotic pressure Replacement of massive blood loss with large volumes of crystalloids, synthetic colloids, and red cell preparations devoid of plasma will lead to a fall in plasma colloid osmotic pressure. This may contribute to the development of the adult respiratory distress syndrome, and transfusion of albumin may be necessary if plasma albumin concentrations fall appreciably.
Traditional regimens for managing massive transfusion include routine use of supplements like fresh frozen plasma or platelets, or both, alkalising agents, and calcium supplements, all in fixed quantities according to the amount of blood transfused. This is wasteful, possibly dangerous, and often unnecessary. The need for supplements should be judged by careful clinical assessment and frequent laboratory measurements, so that each patient receives the optimum treatment.
ANY QUESTIONS
Is it known whether habitual physical exercise into middle age in men has a protective effect against prostatic disorders, especially benign hypertrophy? Is there any evidence for a hormonally mediated effect?
Little has been written about the relation between prostatic disease and physical exercise. Epidemiological studies suggest an inverse relation between exercise and the incidence of carcinoma of the prostate. A similar relation exists with other malignant tumours such as those of the breast and colon.2 There are, however, no such data relating to benign prostatic disease.
One study measured the effect on male endocrinology of 48 hours of physical exercise. There was a significant rise in oestrogen concentrations followed by a smaller secondary fall in the concentrations of circulating androgens. I Benign prostatic hyperplasia and carcinoma of the prostate are hormone dependent diseases. Neither condition occurs in men castrated before puberty, and both benign prostatic hyperplasia and carcinoma respond to withdrawal of androgens. The aetiology of benign prostatic hyperplasia seems to be related to the accumulation of dihydrotestosterone within the prostate. The action of this hormone is enhanced by oestrogens, which increase the amount of androgen receptor within the gland. Thus rising concentrations of oestrogens in elderly men may allow the development of benign prostatic hyperplasia despite a fall in the production of testosterone over the age of 60.4 Regular exercise, especially for short periods, may create a suitable hormonal environment for the development of benign prostatic hyperplasia. Data supporting such a hypothesis, however, are lacking, and whether physical exercise is a factor influencing the development of benign prostatic hyperplasia must remain open to question. -J G GINGELL, consultant urologist, and D CHADWICK, research registrar, Bristol
